A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma

NCT00269113 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Hodgkin's Lymphoma

Interventions

DRUG: rituximab [MabThera/Rituxan]
DRUG: Standard chemotherapy

Sponsor

Hoffmann-La Roche